Aurobindo Pharma Limited (NSEI: AUROPHARMA)
Health Care · Pharmaceuticals · IN
Rs1,621.30
-0.05% today · +54.4% 1Y
Aurobindo Pharma Limited (NSEI: AUROPHARMA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $9.75B and employs 29,209 people.
Over the last twelve months the share price has gained 54.4%, trading between 1.02K and 1.68K.
Tweenvest scores Aurobindo Pharma Limited across four factors: quality 81/100, value 25/100, growth 53/100, dividend 13/100. Its strongest factor is quality.
AUROPHARMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.75B
- Revenue (TTM)
- $3.69B
- P/E
- 25.34
- EPS
- 63.99
- Dividend yield
- 0.49%
- Beta (5Y)
- 0.02
- 52-week high
- Rs1,682.40
- 52-week low
- Rs1,016.10
- Avg volume (3M)
- —
- Shares outstanding
- 575.38M
- Employees
- 29,209
- Next earnings
- —
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
- ISIN
- INE406A01037
- Founded
- 1986
- Listed since
- Jan 15, 1996
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.16 | +0.34% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.18 | -0.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.23% |
Figures last refreshed Aug 18, 2026.